Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Capital Expenditures (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Capital Expenditures for 8 consecutive years, with $19000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 80.41% to $19000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85000.0 through Dec 2025, down 66.0% year-over-year, with the annual reading at $85000.0 for FY2025, 66.0% down from the prior year.
  • Capital Expenditures for Q4 2025 was $19000.0 at Precision Biosciences, up from $2000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $1.7 million in Q2 2021, with the low at -$26000.0 in Q4 2023.
  • Average Capital Expenditures over 5 years is $561263.2, with a median of $521000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures crashed 104.11% in 2023, then soared 473.08% in 2024.
  • Over 5 years, Capital Expenditures stood at $1.5 million in 2021, then crashed by 58.01% to $632000.0 in 2022, then plummeted by 104.11% to -$26000.0 in 2023, then skyrocketed by 473.08% to $97000.0 in 2024, then plummeted by 80.41% to $19000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $19000.0, $2000.0, and $64000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.